Transcatheter Tricuspid-Valve Repair Plus Medical Therapy Beats Drugs Alone in Severe Regurgitation
Start here
A randomized trial in 360 patients with symptomatic severe tricuspid regurgitation at high risk of heart-failure events found that transcatheter tricuspid-valve repair added to medical therapy outperformed medical therapy alone. The hierarchical composite of death, heart-failure hospitalization, and quality-of-life improvement at 1 year favored the repair group with a win ratio of 2.42 (95% CI, 1.76 to 3.33). Longer-term outcomes also favored intervention: freedom from death or heart-failure hospitalization through 3 years was 52.4% with repair versus 21.0% with medical therapy alone (hazard ratio 0.40). The results, published in the New England Journal of Medicine on August 30, 2026, support adding transcatheter repair to standard drug treatment in this high-risk population.
Written by a model from the reports · updated 2 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- WeChatPickTRIC-I-HF: Transcatheter Tricuspid Repair Cuts 3-Year Death or Heart Failure Hospitalization Risk by 60% Versus Medication Alone
The TRIC-I-HF trial showed that transcatheter tricuspid valve repair combined with medication reduced the risk of death or heart failure hospitalization at 3 years by 60% compared with medication alone in 360 high-risk patients (HR 0.40, NCT04634266).
- New England Journal of MedicinePickTricuspid-Valve Intervention in Heart Failure.
Transcatheter tricuspid-valve repair plus medical therapy beat medical therapy alone in patients with symptomatic severe tricuspid regurgitation at high risk of heart-failure events. In 360 randomized patients, the win ratio for the hierarchical composite of death, heart-failure hospitalization, and quality-of-life improvement at 1 year was 2.42 (95% CI, 1.76 to 3.33). Freedom from death or heart-failure hospitalization through 3 years was 52.4% with repair versus 21.0% without (hazard ratio 0.40).
- New England Journal of MedicineTricuspid-Valve Intervention in Heart Failure
The TRILUMINATE Pivotal trial showed that TriClip transcatheter edge-to-edge repair significantly improves quality of life in heart failure patients with severe tricuspid regurgitation. Compared with medical therapy alone, the TriClip group met the superiority criterion for the primary endpoint, improvement in health status as measured by the Kansas City Cardiomyopathy Questionnaire, at 1 year. The results offer a new treatment option for this high-risk population.
Coverage and heat for this story
Reports so far 3·Heat now 6·Peak heat 10 (Oct 20 00:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.